Special Issue "Role of Medical Imaging in Cancers"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 December 2019

Special Issue Editors

Guest Editor
Prof. Stefano Fanti

Metropolitan Nuclear Medicine, University of Bologna, Bologna, Italy
Website | E-Mail
Interests: PET imaging; PET/CT; molecular imaging; radiopharmaceuticals¸ prostate cancer
Guest Editor
Dr. Laura Evangelista

Nuclear Medicine Unit, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy
Website | E-Mail
Interests: PET imaging; PET/CT; radiopharmaceuticals; prostate cancer; breast cancer

Special Issue Information

Dear Colleagues,

Medical imaging comprises a huge amount of imaging techniques, from ultrasound and computed tomography (CT) to molecular imaging comprising magnetic resonance imaging (MRI) and positron emission tomography (PET).

Molecular imaging allows for the remote, noninvasive sensing and measurement of cellular and molecular processes in living subjects. It provides a window into the biology of cancer from the sub-cellular level to the patient undergoing a new, experimental therapy. Conventional imaging, i.e. CT is critical to the management of patients with cancer, conversely, molecular imaging provides more relevant information, such as the early detection of changes with therapy, identification of patient-specific cellular and metabolic abnormalities, and other specific biological features that have a considerable impact on morbidity and mortality.

Molecular imaging has developed rapidly in the last years, particularly in the oncological field. The development of new hybrid scanners, like digital PET/CT, PET/MRI and SPECT/CT, has significantly improved the detection of tumors in all phases of disease (from the initial stages to the evaluation of the response to therapy). Moreover, the introduction of various radiopharmaceutical agents has opened new scenarios for the in vivo molecular characterization of cancer.

Unfortunately, the barriers associated with the regulatory organs limit the use of these new agents in clinical practice, although an increased amount of preclinical and first human results are now available, particularly for new targeted radiopharmaceuticals. This Special Issue will highlight the role of molecular imaging in cancer management, covering some important aspects by focalizing the attention of new discoveries for the big killers, like prostate cancer, lung cancer, breast cancer and colon cancer.

Prof. Stefano Fanti
Dr. Laura Evangelista
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Molecular imaging
  • PET/CT
  • PET/MRI
  • Radiopharmaceuticals
  • Oncology
  • Targeted therapy
  • Immunotherapy
  • Prognosis

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle 18F-FDG-PET Can Predict Microvessel Density in Head and Neck Squamous Cell Carcinoma
Cancers 2019, 11(4), 543; https://doi.org/10.3390/cancers11040543
Received: 11 March 2019 / Revised: 4 April 2019 / Accepted: 11 April 2019 / Published: 15 April 2019
PDF Full-text (909 KB) | HTML Full-text | XML Full-text
Abstract
Aim: Positron emission tomography (PET) with 18F-fluordeoxyglucose (18F-FDG) plays an essential role in the staging and tumor monitoring of head and neck squamous cell carcinoma (HNSCC). Microvessel density (MVD) is one of the clinically important histopathological features in HNSCC. [...] Read more.
Aim: Positron emission tomography (PET) with 18F-fluordeoxyglucose (18F-FDG) plays an essential role in the staging and tumor monitoring of head and neck squamous cell carcinoma (HNSCC). Microvessel density (MVD) is one of the clinically important histopathological features in HNSCC. The purpose of this study was to analyze possible associations between 18F-FDG-PET findings and MVD parameters in HNSCC. Materials and Methods: Overall, 22 patients with a mean age of 55.2 ± 11.0 and with different HNSCC were acquired. In all cases, whole-body 18F-FDG-PET was performed. For each tumor, the maximum and mean standardized uptake values (SUVmax; SUVmean) were determined. The MVD, including stained vessel area and total number of vessels, was estimated on CD105 stained specimens. All specimens were digitalized and analyzed by using ImageJ software 1.48v. Spearman’s correlation coefficient (r) was used to analyze associations between investigated parameters. p-values of <0.05 were taken to indicate statistical significance. Results: SUVmax correlated with vessel area (r = 0.532, p = 0.011) and vessel count (r = 0.434, p = 0.043). Receiver operating characteristic analysis identified a threshold SUVmax of 15 to predict tumors with high MVD with a sensitivity of 72.7% and specificity of 81.8%, with an area under the curve of 82.6%. Conclusion: 8F-FDG-PET parameters correlate statistically significantly with MVD in HNSCC. SUVmax may be used for discrimination of tumors with high tumor-related MVD. Full article
(This article belongs to the Special Issue Role of Medical Imaging in Cancers)
Figures

Figure 1

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top